# Temporary mechanical circulatory support (heart pumps)

Technology · id `cardio:mechanical-circulatory-support` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: MCS

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

Temporary mechanical circulatory support means a pump or similar device that helps the heart pump blood for a limited time. A 2026 review of randomized trials in adults with cardiogenic shock after a heart attack looked at three kinds: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. The review says no device gives universal benefit in this varied group. Routine Impella CP support lowered 180-day mortality in carefully selected patients in one trial, with more major bleeding and other complications.

## Technical summary

MeSH descriptor D006353 (Heart-Assist Devices) is recorded as a broad match: its scope note describes small pumps, often implantable, designed for temporarily assisting the heart, usually the left ventricle, to pump blood. FDA product code OZD (Temporary Non-Roller Type Left Heart Support Blood Pump) is also broad, and it covers left-heart pumps only. The US approval facts are for one device family, the Impella left-heart pumps (premarket approval P140003). The trial evidence comes from the abstract of one 2026 review, not from the trial reports.

## Claims, with the population each applies to

## Context: Adults with cardiogenic shock after an acute heart attack, as covered by a 2026 review of randomized trials of temporary mechanical circulatory support

Recipient: Adult; Population: Adult patients with acute myocardial infarction-related cardiogenic shock (AMI-CS), as the abstract states the review population. The review looked at randomized trials and analyses of them from January 2021 through June 2026.; Care setting: Hospital intensive care and shock systems of care; the abstract mentions experienced shock systems; Geography: Not stated in the abstract; Life stage: Adults; Follow-up: Not applicable (review). The abstract names 180-day mortality for one trial and gives no other follow-up.

### The abstract of a 2026 open-access review of randomized trials in adults with cardiogenic shock after an acute heart attack covers three kinds of temporary support: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. It says recent randomized evidence shows that no temporary support device gives universal benefit across this varied group. It says routine balloon pump use has not been linked to better survival. It says the DanGer Shock trial showed lower 180-day mortality with routine Impella CP support in carefully selected patients with STEMI-related cardiogenic shock, with more major bleeding, limb ischemia, acute kidney injury and renal replacement therapy. It says other trials did not show a survival benefit from routine early venoarterial extracorporeal membrane oxygenation in broad populations. The review concludes that the role of temporary support has moved from routine device use toward individualized, phenotype-guided therapy, and that Impella CP should be used selectively in patients with mainly left ventricular failure treated within experienced shock systems.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients with acute myocardial infarction-related cardiogenic shock (AMI-CS), as the abstract states the review population. The review looked at randomized trials and analyses of them from January 2021 through June 2026.; Care setting: Hospital intensive care and shock systems of care; the abstract mentions experienced shock systems; Geography: Not stated in the abstract; Life stage: Adults; Follow-up: Not applicable (review). The abstract names 180-day mortality for one trial and gives no other follow-up.
- Limitations: Only the abstract of the review was read. The trial reports, the numbers of deaths and the review's search and selection methods beyond the abstract were not read, so the atlas records no effect size. The statements on DanGer Shock and the other trials are the review's, not read from the trial reports. A review summarizes trials and is not a trial. The review limits itself to heart-attack-related cardiogenic shock in adults and does not cover cardiogenic shock from other causes.
- Last checked: 2026-10-30
- Sources:
  1. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 1. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Background of the review.
  2. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 3. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Population of the review.
  3. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 4, fragment 1 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Kinds of support covered.
  4. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 4, fragment 2 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Kinds of support covered.
  5. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 6. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Main result.
  6. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 7, fragment 1 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Balloon pump.
  7. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 8, fragment 2 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: DanGer Shock result.
  8. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 9. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Harms that came with the benefit.
  9. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 11, fragment 1 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Extracorporeal membrane oxygenation trials.
  10. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 13. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Conclusion.
  11. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 14, fragment 1 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Selective use of Impella CP.
  12. Supports: Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13665844/>
     Locator: Abstract, sentence 14, fragment 2 of 2. Retrieved 2026-10-30T19:47:09Z. Source state: Current. Version fingerprint: ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c.
     How it applies: Selective use of Impella CP.

## Context: Patients described in the US premarket approval orders for the Impella heart pump (high-risk PCI, and cardiogenic shock after heart attack, heart surgery, cardiomyopathy or myocarditis)

Recipient: Recipient not specified; Population: The approval orders describe patients undergoing high-risk percutaneous coronary intervention with severe coronary artery disease and depressed left ventricular ejection fraction (2015), and patients with ongoing cardiogenic shock from isolated left ventricular failure after acute myocardial infarction or open heart surgery (2016), or in the setting of cardiomyopathy or myocarditis (2018).; Care setting: Not stated in the FDA records beyond a hospital procedure or intensive care implied by the indications; Geography: United States (decisions by the US Food and Drug Administration); Life stage: Not stated in the FDA records; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### The openFDA record of premarket approval P140003, with Abiomed, Inc. as applicant, lists approval of the IMPELLA 2.5 System on 23 March 2015. The approval order describes a temporary ventricular support device used during high-risk percutaneous coronary intervention in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction. Supplement S004, approved on 7 April 2016, states an indication for ongoing cardiogenic shock that occurs within 48 hours after acute myocardial infarction or open heart surgery, as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures. Supplement S018, approved on 7 February 2018, states an indication for ongoing cardiogenic shock that occurs immediately after those events or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis, again as a result of isolated left ventricular failure that is not responsive to optimal medical management.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: The approval orders describe patients undergoing high-risk percutaneous coronary intervention with severe coronary artery disease and depressed left ventricular ejection fraction (2015), and patients with ongoing cardiogenic shock from isolated left ventricular failure after acute myocardial infarction or open heart surgery (2016), or in the setting of cardiomyopathy or myocarditis (2018).; Care setting: Not stated in the FDA records beyond a hospital procedure or intensive care implied by the indications; Geography: United States (decisions by the US Food and Drug Administration); Life stage: Not stated in the FDA records; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: This claim covers one device family, the Impella left-heart pumps approved under P140003 (product code OZD). It does not cover other temporary support, such as the intra-aortic balloon pump or venoarterial extracorporeal membrane oxygenation, or the Impella RP, which has its own approval. Only three of the many records for P140003 are read, and later supplements may change the wording. An FDA approval is a decision about a device, not a finding about how well it works. The approval orders are paraphrased from the openFDA statements, which openFDA says it does not validate and not to rely on for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].pma\_number. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Approval number.
  2. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].applicant. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Applicant.
  3. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].trade\_name. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Trade name of the original approval.
  4. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].decision\_date. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Decision date of the original approval.
  5. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].decision\_code. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Decision code (APPR).
  6. Supports: FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements) (Regulator, edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003&sort=decision_date:asc&limit=3>
     Locator: results\[0\].ao\_statement. Retrieved 2026-10-30T19:46:25Z. Source state: Current. Version fingerprint: 7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44.
     How it applies: Approval order statement of the original approval.
  7. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[0\].supplement\_number. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Supplement S004.
  8. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[0\].decision\_date. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Decision date of S004.
  9. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[0\].ao\_statement. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Approval order statement of S004.
  10. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[2\].supplement\_number. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Supplement S018.
  11. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[2\].decision\_date. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Decision date of S018.
  12. Supports: FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records) (Regulator, edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.) <https://api.fda.gov/device/pma.json?search=pma_number:P140003+AND+ao_statement:cardiogenic&sort=decision_date:asc&limit=10>
     Locator: results\[2\].ao\_statement. Retrieved 2026-10-30T19:46:39Z. Source state: Current. Version fingerprint: 03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd.
     How it applies: Approval order statement of S018.

## Connected pages

- Filed under this front: Devices and monitoring (`cardio:front-devices-and-monitoring`)
- Related to: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Related to: Extracorporeal membrane oxygenation (ECMO) (`cardio:extracorporeal-membrane-oxygenation-ecmo`)
- Related to: Left ventricular assist device (LVAD) implantation (`cardio:left-ventricular-assist-device-lvad-implantation`)
- Related to: Extracorporeal membrane oxygenation circuit (`cardio:extracorporeal-membrane-oxygenation-circuit`)
- Related to: Left ventricular assist device (`cardio:left-ventricular-assist-device`)

## Provenance

Content hash: 9b6fb7ba7086d7c82aa083e9942136b551d13f2425e9ae00d5384de18f079b6f
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
